Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus

Arthritis Research and Therapy

Volumn 6, Issue 4, 2004, Pages 169-173

  Alarcón Riquelme, Marta E ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Autoimmunity; Repression; Runt domain; Susceptibility; Transcription

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CANCER; DISEASE COURSE; GENETIC SUSCEPTIBILITY; HUMAN; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORE BINDING FACTOR ALPHA 3 SUBUNIT; CORE BINDING FACTOR ALPHA SUBUNITS; DNA-BINDING PROTEINS; HUMANS; LINKAGE (GENETICS); LUPUS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; PSORIASIS; TRANSCRIPTION FACTORS;

EID: 4444381493     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002, 32:666-669.
2. Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST: Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 2003, 62:492-497.
3. Prokunina L, Padyukov L, Bennet A, De Faire U, Wiman B, Prince J Alfredsson L, Klareskog L, Alarcón-Riquelme ME: Association of the PD1.3 A allelle of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 2004, 50:1770-1773.
4. Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, Heffernan M, Daw JA, Robarge J, Ott J, et al.: A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet 2003.
5. Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, et al.: An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 2003, 35:341-348.
6. John S, Eyre S, Myerscough A, Barrett J, Silman A, Ollier W, Worthington J: Linkage and association analysis of candidate genes in rheumatoid arthritis. J Rheumatol 2001, 28:1752-1755.
7. Rioux JD, Daly MJ, Silverberg MS, Lindblad K, Steinhart H, Cohen Z, Delmonte T, Kocher K, Miller K, Guschwan S, et al.: Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001, 29:223-228.
8. Otto F, Lubbert M, Stock M: Upstream and downstream targets of RUNX proteins. J Cell Biochem 2003, 89:9-18.
9. Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura J, Shiina M, Sato K, Kumasaka T, Yamamoto M, et al.: Structural analyses of DNA recognition by the AMLl/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell 2001, 104: 755-767.
10. Backstrom S, Huang SH, Wolf-Watz M, Xie XQ, Hard T, Grundstrom T, Sauer UH: Crystallization and preliminary studies of the DNA-binding runt domain of AML1. Acta Crystallogr D Biol Crystallogr 2001, 57:269-271.
11. Rennert J, Coffman JA, Mushegian AR, Robertson AJ: The evolution of Runx genes I. A comparative study of sequences from phylogenetically diverse model organisms. BMC Evol Biol 2003, 3:4.
12. Coffman JA: Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol Int 2003, 27:315-324.
13. Barton K, Nucifora G: AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia. BioEssays 2000, 22: 214-218.
14. Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H: Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992, 80:1825-1831.
15. Guerrasio A, Rosso C, Martinelli G, Lo Coco F, Pampinelia M, Santoro A, Lanza C, Allione B, Resegotti L, Saglio G: Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continous clinical remission. Br J Haematol 1995, 90:364-368.
16. Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H, Kamada N, Ohki M: Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 1993, 82:1270-1276.
17. Uchida H, Downing JR, Miyazaki Y, Frank R, Zhang J, Nimer SD: Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. Oncogene 1999, 18:015-1022.
18. Song H, Kim JH, Rho JK, Park SY, Kim CG, Choe SY: Functional characterization of TEL/AML1 fusion protein in the regulation of human CR1 gene promoter. Mol Cells 1999, 9:560-563.
19. Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA: The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995, 85: 3662-3670.
20. Kurokawa M, Ogawa S, Tanaka T, Mitani K, Yazaki Y, Witte ON, Hirai H: The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Oncogene 1995, 11:833-840.
21. Lutterbach B, Hou Y, Durst KL, Hiebert SW: The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc Natl Acad Sci USA 1999, 96:12822-12827.
22. Okuda T, Nishimura M, Nakao M, Fujita Y: RUNX1/AML1: a central player in hematopoiesis. Int J Hematol 2001, 74:252-257.
23. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, et al.: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999, 23:166-175.
24. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind WH, et al.: In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002, 99:1364-1372.
25. Komori T: Requisite roles of Runx2 and Cbfb in skeletal development. J Bone Miner Metab 2003, 21:193-197.
26. Kundu M, Javed A, Jeon JP, Horner A, Shum L, Eckhaus M, Muenke M, Lian JB, Yang Y, Nuckolls GH, et al.: Cbfβ interacts with Runx2 and has a critical role in bone development. Nat Genet 2002, 32:639-644.
27. Lian JB, Balint E, Javed A, Drissi H, Vitti R, Quinlan EJ, Zhang L, Van Wijnen AJ, Stein JL, Speck N, et al.: Runx1/AML1 hematopoietic transcription factor contributes to skeletal development in vivo. J Cell Physiol 2003, 196:301-311.
28. Inoue K, Ozaki S, Ito K, Iseda T, Kawaguchi S, Ogawa M, Bae SC, Yamashita N, Itohara S, Kudo N, et al.: Runx3 is essential for the target-specific axon pathfinding of trkc-expressing dorsal root ganglion neurons. Blood Cells Mol Dis 2003, 30:157-160.
29. Moss SF: RUNX 3, apoptosis O: a new gastric tumour suppressor. Gut 2003, 52:12-13.
30. Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, Bernstein Y, Goldenberg D, Brenner O, Berke G, et al.: Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA 2003, 100:7731-7736.
31. Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, Komori T, Ito Y, Littman DR: Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 2002, 111:621-633.
32. Komine O, Hayashi K, Natsume W, Watanabe T, Seki Y, Seki N, Yagi R, Sukzuki W, Tamauchi H, Hozumi K, et al.: The Runx1 transcription factor inhibits the differentiation of naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression. J Exp Med 2003, 198:51-61.
33. Fainaru O, Woolf E, Lotem J, Yarmus M, Brenner O, Goldenberg D, Negreanu V, Bernstein Y, Levanon D, Jung S, et al.: Runx3 regulates mouse TGFβ-mediated dendritic cell function and its absence results in airway inflammation. EMBO J 2004, 23:969-979.
34. Petrow PK, Hummel KM, Schedel J, Franz JK, Klein CL, Muller-Ladner U, Kriegsmann J, Chang PL, Prince CW, Gay RE, et al.: Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum 2000, 43:1597-1605.
35. Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, Kobayashi H, Shimizu M, Katada Y, Wakitani S, et al.: Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 2002, 29:2061-2067.
36. Stricker S, Fundele R, Vortkamp A, Mundlos S: Role of Runx genes in chondrocyte differentiation. Dev Biol 2002, 245:95-108.
37. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, Paleolog EM: Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001, 44:2055-2064.
38. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN: Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998, 41:1258-1265.
39. Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, Lopez-Otin C: Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum 1997, 40:1391-1399.
40. Detmar M: Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J Invest Dermatol 2004, 122:xiv-xv.
41. Balomenos D, Martin-Caballero J, Garcia MI, Prieto I, Flores JM, Serrano M, Martinez AC: The cell cycle inhibitor p2l controls T-cell proliferation and sex-linked lupus development. Nat Med 2000, 6:171-176.
42. Iida K, Mornaghi R, Nussenzweig V: Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med 1982, 155:1427-1438.
43. Moulds JM, Reveille JD, Arnett FC: Structural polymorphisms of complement receptor 1 (CR1) in systemic lupus erythematosus (SLE) patients and normal controls of three ethnic groups. Clin Exp Immunol 1996,105:302-305.
44. Banerjee C, Hiebert SW, Stein JL, Lian JB, Stein GS: An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteocalcin gene. Proc Natl Acad Sci USA 1996, 93:4968-4973.
45. Hoffmann HM, Beumer TL, Rahman S, McCabe LR, Banerjee C, Aslam F, Tiro JA, van Wijnen AJ, Stein JL, Stein GS, et al.: Bone tissue-specific transcription of the osteocalcin gene: role of an activator osteoblast-specific complex and suppressor hox proteins that bind the OC box. J Cell Biochem 1996, 61:310-324.
46. Prince M, Banerjee C, Javed A, Green J, Lian JB, Stein GS, Bodine PV, Komm BS: Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts. J Cell Biochem 2001, 80:424-440.
47. Bae SC, Lee KS, Zhang YW, Ito Y: Intimate relationship between TGF-beta/BMP signaling and runt domain transcription factor, PEBP2/CBF. J Bone Joint Surg Am 2001, 83-A Suppl 1:S48-S55.
48. Leboy P, Grasso-Knight G, D'Angelo M, Volk SW, Lian JV, Drissi H, Stein GS, Adams SL: Smad-Runx interactions during chondrocyte maturation. J Bone Joint Surg Am 2001, 83-A Suppl 1: S15-S22.
49. Ito Y, Miyazono K: RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev 2003, 13:43-47.
50. Alarcon-Riquelme ME: A RUNX trio with a taste for autoimmunity. Nat Genet 2003, 35:299-300.